Lene Wohlfahrt Dreyer

Medicine and Dentistry

1. Patient 100%
2. Inpatient 81%
3. Rheumatoid Arthritis 76%
4. Cohort Analysis 55%
5. Therapeutic Procedure 50%
6. Psoriatic Arthritis 46%
7. TNF Inhibitor 19%
8. Spondylarthritis 18%
9. Pain 18%
10. Rheumatology 18%
11. Disease Modifying Antirheumatic Drug 17%
12. Disease Activity 15%
13. Psoriasis 14%
14. Systemic Lupus Erythematosus 14%
15. Fatigue 13%
16. Infection 12%
17. Incidence 12%
18. Follow up 12%
19. Abatacept 12%
20. Biological Product 11%
21. Diseases 10%
22. Analysis 9%
23. Randomized Controlled Trial 9%
24. Health Care 8%
25. Janus Kinase Inhibitor 8%
26. Cancer Risk 8%
27. Outpatient 8%
28. Hazard Ratio 7%
29. Cohort Study 7%
30. Person 7%
31. Patient-Reported Outcome 7%
32. Smoking 7%
33. Disease-Modifying Antirheumatic Drug 7%
34. Population 6%
35. Ankylosing Spondylitis 6%
36. Age 6%
37. Gene Linkage 6%
38. Association 6%
39. Hand Osteoarthritis 6%
40. Drug 6%
41. Subacute Cutaneous Lupus Erythematosus 5%
42. COVID-19 5%
43. Operation on Joint 5%
44. Gout 5%
45. Rituximab 5%
46. Tocilizumab 5%
47. Etanercept 5%
48. Drug Therapy 5%
49. Proportional Hazards Model 5%
50. Health Assessment Questionnaire 5%